

Supplementary Table 1. Prevalence of APOs and PH-RDs in pregnant women during 2018~2023

	<i>N = 102427</i>
PH-RD	2536 (2.48)
SLE	308 (0.30)
pSS	164 (0.16)
UCTD	199 (0.19)
APS	2000 (1.95)
Singleton pregnancy	94, 353 (92.12)
live birth	91, 267 (96.73)
preterm birth	7485 (7.93)
preeclampsia	2836 (3.01)
FGR	1587 (1.68)
GDM	19, 200 (20.35)
Gestational hypertension	1712 (1.81)
Placental abruption	1385 (1.47)
Oligohydramnios	2575 (2.73)
Polyhydramnios	2751 (2.92)
Thrombosis	441 (0.47)

APO: adverse pregnancy outcome; PH-RD: pregnancy-harmful rheumatic disease; SLE: systemic lupus erythematosus; pSS: primary Sjogren's syndrome; UCTD: undifferentiated connective tissue diseases; APS: antiphospholipid syndrome; FGR: fetal growth restriction; GDM: gestational diabetes mellitus. Data are presented number(percentage).

Supplementary Table 2. Tendency of annual incidence of PH-RDs and APOs from 2018 to 2023

	R²	P	B
SLE	0.705	0.036	0
pSS	0.111	0.519	0
UCTD	0.915	0.003	0.001
APS	0.270	0.291	0.002
live birth	0.459	0.139	-0.001
preterm birth	0.830	0.012	-0.005
preeclampsia	0.031	0.737	0.000
FGR	0.964	<0.001	0.003

APO: adverse pregnancy outcomes; RD: rheumatic disease; SLE: systemic lupus erythematosus; pSS: primary Sjogren's syndrome; UCTD: undifferentiated connective tissue diseases; APS: antiphospholipid syndrome; FGR: fetal growth restriction.